Trial Profile

A phase 1, first in human trial investigating AWAKE-LM-TT in the treatment of pancreatic cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AWAKE-LM-TT (Primary)
Indications Pancreatic cancer
Focus Adverse reactions; First in man
Sponsors Loki Therapeutics

Most Recent Events

30 Mar 2022 New trial record
28 Mar 2022 According to a Loki Therapeutics media release, company plans to file an Investigational New Drug (IND) application with the U.S. Food & Drug Administration.
28 Mar 2022 According to a Loki Therapeutics media release, company anticipates initiating this trial in the second half of 2022, after receiving FDA clearance for the IND.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com